Aeluma Beats Low Bar, But Shrinking Revenue And Unsigned Deals Keep It In A Holding Pattern

Aeluma (NASDAQ: ALMU) cleared a modest bar in its fiscal first quarter, but the beat says little about its trajectory. The company reported a non-GAAP loss of $0.12 per share, a penny better than the -$0.13 consensus, for a 7.7% earnings surprise. Revenue of $0.57 million topped the $0.5 million estimate by 13.6%. Measured against a year ago, however, the picture deteriorated. Earnings fell 300.0% year over year, and revenue dropped 59.0%. The central tension is that the AI datacom story keeps growing in ambition while the commercial evidence remains unsigned. The opportunity management describes keeps getting larger, but the reported business keeps getting smaller.

The quality of the beat deserves scrutiny. On a GAAP basis, the net loss widened to $3.8 million, or $0.19 per share, from $1.5 million, or $0.09, a year earlier. Adjusted EBITDA loss expanded to $2.7 million from $0.45 million. There was some sequential relief:

• Non-GAAP loss per share narrowed from $0.15 in the June quarter.
• Adjusted EBITDA loss improved from $2.9 million.
• Total operating expenses edged down to $4.8 million from $5.0 million.

Revenue, however, was essentially flat sequentially at $568,000 versus $582,000. It sits well below the $1.2 million posted in the third quarter of fiscal 2026 and the $1.4 million of a year ago. All of it still comes primarily from R&D contracts, and there is no commercial revenue yet. One telling detail: interest income of $492,000 nearly matched quarterly revenue, a reminder that the balance sheet, not the business, is doing much of the work.

The conference call reinforced that this was a holding-pattern quarter. Management again pointed to a significant volume ramp in 2028 and beyond, with customer-specific qualification expected to take 9 to 18 months. Fiscal 2027 revenue is therefore limited to R&D contracts and non-recurring engineering work, and no new guidance was issued. Government R&D work is being deprioritized as AI datacom dominates the narrative. The earlier mobile SWIR thesis and initial sales orders mentioned in prior quarters have largely faded from the discussion.

At the same time, management escalated its market framing. It cited U.S. AI infrastructure investment reaching an aggregate $10.3 trillion by 2032, up from the $1.8 trillion data center capex figure it referenced last quarter. Bears have legitimate ammunition when the addressable-market language expands faster than the revenue line.

There were tangible steps forward:

• **Aixtron agreement:** The MOCVD purchase, flagged as planned last quarter, is now a finalized agreement for a 200 mm capable system on gallium arsenide and silicon substrates. Management framed it as an accelerant rather than a requirement, given existing in-house and Sumitomo capacity.
• **Customer discussions:** These expanded further, including negotiations on non-recurring engineering funding and potentially high-volume opportunities tied to the 2028-2032 buildout.
• **Industry validation:** Momentum behind slow-and-wide architectures, including the OCP workstream and OCI-MSA, aligns with the LINX S-series photodetectors.
• **Supply-chain thesis:** Management cited Marvell's agreement to acquire Lumentum as evidence of indium phosphide supply constraints, which supports Aeluma's argument for alternative substrates.

The execution risk, though, is now about conversion. The "several multi-million dollar" NRE agreements discussed last quarter remain unannounced. The up-to-$30 million CHIPS funding, under letter of intent since July, is still in diligence and negotiation. There is also a strategic wrinkle: Aeluma may compete with Tier 1 suppliers that are also prospective customers or channels.

Liquidity is not an immediate concern. Cash stood at $53.9 million, down from $56.0 million, with operating cash burn of $1.7 million in the quarter. Still, the Aixtron system adds capital spending ahead of any commercial revenue, which makes the CHIPS award more consequential.

The market had already turned decisively skeptical before the report. Shares entered earnings at $7.21, down 35.7% from the $11.21 open after the September report and roughly 55% below the 200-day moving average of $16.20. The stock peaked at $13.94 in late September and slid to a 52-week low of $5.87 on November 5. It bounced about 23% off that low heading into the release. Investor sentiment stood at a deeply negative -0.69, and the Earnings Whispers price and AVWAP trend readings remain negative. In that context, a narrow beat against depressed expectations offers limited relief. It does not resolve the timing questions behind the sell-off.

The bottom line is that Aeluma delivered a cosmetic beat on a quarter that changed little. Losses narrowed modestly from the prior quarter, the Aixtron deal moved from plan to contract, and customer engagement reportedly broadened. Yet revenue is less than half its year-ago level, commercial sales remain years away, and the catalysts investors are waiting for are still unsigned. Until NRE contracts or the CHIPS agreement are finalized, the story rests on a widening total addressable market narrative rather than reported results, and the stock's steep decline suggests investors are demanding proof rather than projections.

Read our earnings preview for Aeluma, Inc.: https://www.earningswhispers.com/article/ALMU/22966

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.